Analysis of Profitability Ratios
Quarterly Data
Profitability ratios measure the company’s ability to generate profitable sales from its resources (assets).
Profitability Ratios (Summary)
AbbVie Inc., profitability ratios (quarterly data)
Based on: 10-K (filing date: 2021-02-19), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-04), 10-Q (filing date: 2020-05-08), 10-K (filing date: 2020-02-21), 10-Q (filing date: 2019-11-06), 10-Q (filing date: 2019-08-05), 10-Q (filing date: 2019-05-03), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-07), 10-Q (filing date: 2018-08-07), 10-Q (filing date: 2018-05-04), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06).
Profitability ratio | Description | The company |
---|---|---|
Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | AbbVie Inc.’s gross profit margin ratio deteriorated from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020. |
Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | AbbVie Inc.’s operating profit margin ratio deteriorated from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020. |
Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | AbbVie Inc.’s net profit margin ratio deteriorated from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020. |
Profitability ratio | Description | The company |
---|---|---|
ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | AbbVie Inc.’s ROE improved from Q2 2020 to Q3 2020 but then deteriorated significantly from Q3 2020 to Q4 2020. |
ROA | A profitability ratio calculated as net income divided by total assets. | AbbVie Inc.’s ROA improved from Q2 2020 to Q3 2020 but then deteriorated significantly from Q3 2020 to Q4 2020. |
Gross Profit Margin
AbbVie Inc., gross profit margin calculation (quarterly data)
Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
Gross margin | 9,174 | 7,852 | 6,714 | 6,677 | 6,698 | 6,559 | 6,436 | 6,134 | 6,283 | 6,401 | 6,344 | 6,007 | 5,459 | 5,379 | 5,416 | 4,922 | 5,241 | 4,928 | 5,047 | 4,589 | ||||||
Net revenues | 13,858 | 12,902 | 10,425 | 8,619 | 8,704 | 8,479 | 8,255 | 7,828 | 8,305 | 8,236 | 8,278 | 7,934 | 7,739 | 6,995 | 6,944 | 6,538 | 6,796 | 6,432 | 6,452 | 5,958 | ||||||
Profitability Ratio | ||||||||||||||||||||||||||
Gross profit margin1 | 66.41% | 68.74% | 73.56% | 77.43% | 77.64% | 77.32% | 77.41% | 77.07% | 76.44% | 75.22% | 74.93% | 75.18% | 75.05% | 76.85% | 76.78% | 76.81% | 77.25% | — | — | — | ||||||
Benchmarks | ||||||||||||||||||||||||||
Gross Profit Margin, Competitors2 | ||||||||||||||||||||||||||
Abbott Laboratories | 50.49% | 50.18% | 50.97% | 52.13% | 52.46% | 52.39% | 52.17% | 51.57% | 51.32% | 50.57% | 50.38% | 49.39% | 47.75% | 48.59% | 49.21% | 51.32% | 54.09% | — | — | — | ||||||
Amgen Inc. | 74.59% | 75.55% | 77.15% | 78.90% | 80.38% | 81.19% | 81.23% | 81.26% | 81.80% | 81.61% | 81.78% | 81.69% | 81.33% | 81.37% | 81.26% | 81.05% | 80.99% | — | — | — | ||||||
Bristol-Myers Squibb Co. | 72.31% | 71.18% | 69.47% | 68.02% | 69.10% | 69.90% | 70.10% | 70.86% | 70.98% | 70.37% | 70.12% | 69.62% | 70.80% | 71.92% | 72.78% | 74.19% | 74.54% | — | — | — | ||||||
Eli Lilly & Co. | 77.66% | 78.26% | 78.67% | 79.22% | 78.85% | 77.78% | 76.67% | 74.96% | 73.81% | 73.39% | 72.92% | 72.95% | 73.46% | 73.69% | 73.89% | 73.78% | 73.35% | — | — | — | ||||||
Gilead Sciences Inc. | — | 78.72% | 78.25% | 79.06% | 78.86% | 79.27% | 78.98% | 78.02% | 77.61% | 79.21% | 80.31% | 81.82% | 82.97% | 84.51% | 84.71% | 85.95% | 85.77% | 86.36% | 86.91% | 86.69% | ||||||
Illumina Inc. | 68.01% | 69.02% | 70.34% | 70.36% | 69.63% | 69.24% | 68.84% | 69.06% | 69.01% | 69.44% | 68.85% | 67.98% | 66.35% | 65.68% | 66.26% | 67.53% | 69.48% | — | — | — | ||||||
Johnson & Johnson | 65.58% | 65.68% | 65.66% | 66.15% | 66.42% | 66.49% | 66.67% | 66.80% | 66.79% | 66.36% | 65.69% | 66.22% | 66.84% | 68.20% | 69.35% | 69.88% | 69.84% | — | — | — | ||||||
Merck & Co. Inc. | 67.74% | 71.23% | 70.06% | 70.11% | 69.87% | 70.13% | 69.89% | 68.94% | 68.06% | 67.35% | 67.81% | 68.22% | 68.16% | 68.09% | 67.92% | 66.61% | 65.10% | — | — | — | ||||||
Pfizer Inc. | 79.26% | 79.86% | 79.94% | 79.94% | 80.25% | 79.85% | 79.91% | 79.36% | 79.03% | 78.58% | 78.24% | 78.48% | 78.61% | 78.66% | 78.15% | 77.28% | 76.66% | — | — | — | ||||||
Regeneron Pharmaceuticals Inc. | 86.82% | 87.98% | 88.21% | 89.72% | 90.05% | 91.14% | 92.27% | 92.79% | 93.53% | 93.36% | 93.28% | 92.95% | 93.24% | 93.37% | 94.16% | 94.53% | 93.83% | — | — | — | ||||||
Vertex Pharmaceuticals Inc. | 88.14% | 88.01% | 87.71% | 87.24% | 86.84% | 86.60% | 86.56% | 86.74% | 86.56% | 86.88% | 87.31% | 87.59% | 88.95% | 89.04% | 89.08% | 89.76% | 87.64% | — | — | — | ||||||
Zoetis Inc. | 69.18% | 69.64% | 69.73% | 69.51% | 68.18% | 67.38% | 66.92% | 66.49% | 67.19% | 68.12% | 68.04% | 67.31% | 66.55% | 65.14% | 64.91% | 65.30% | 65.92% | — | — | — |
Based on: 10-K (filing date: 2021-02-19), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-04), 10-Q (filing date: 2020-05-08), 10-K (filing date: 2020-02-21), 10-Q (filing date: 2019-11-06), 10-Q (filing date: 2019-08-05), 10-Q (filing date: 2019-05-03), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-07), 10-Q (filing date: 2018-08-07), 10-Q (filing date: 2018-05-04), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06).
1 Q4 2020 Calculation
Gross profit margin = 100
× (Gross marginQ4 2020
+ Gross marginQ3 2020
+ Gross marginQ2 2020
+ Gross marginQ1 2020)
÷ (Net revenuesQ4 2020
+ Net revenuesQ3 2020
+ Net revenuesQ2 2020
+ Net revenuesQ1 2020)
= 100 × (9,174 + 7,852 + 6,714 + 6,677)
÷ (13,858 + 12,902 + 10,425 + 8,619)
= 66.41%
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | AbbVie Inc.’s gross profit margin ratio deteriorated from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020. |
Operating Profit Margin
AbbVie Inc., operating profit margin calculation (quarterly data)
Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
Operating earnings | 3,753 | 3,255 | 752 | 3,603 | 3,956 | 2,617 | 3,400 | 3,010 | (2,441) | 3,159 | 2,762 | 2,903 | 1,794 | 2,705 | 2,674 | 2,419 | 2,358 | 2,361 | 2,387 | 2,278 | ||||||
Net revenues | 13,858 | 12,902 | 10,425 | 8,619 | 8,704 | 8,479 | 8,255 | 7,828 | 8,305 | 8,236 | 8,278 | 7,934 | 7,739 | 6,995 | 6,944 | 6,538 | 6,796 | 6,432 | 6,452 | 5,958 | ||||||
Profitability Ratio | ||||||||||||||||||||||||||
Operating profit margin1 | 24.81% | 28.45% | 30.17% | 39.86% | 39.03% | 20.04% | 21.85% | 19.88% | 19.49% | 32.99% | 32.84% | 34.03% | 33.99% | 37.24% | 36.74% | 36.33% | 36.60% | — | — | — | ||||||
Benchmarks | ||||||||||||||||||||||||||
Operating Profit Margin, Competitors2 | ||||||||||||||||||||||||||
Abbott Laboratories | 15.48% | 13.39% | 12.78% | 14.18% | 14.21% | 13.74% | 13.27% | 12.31% | 11.94% | 10.45% | 10.11% | 8.92% | 6.30% | 7.89% | 8.77% | 11.03% | 15.27% | — | — | — | ||||||
Amgen Inc. | 37.70% | 38.59% | 39.76% | 41.89% | 43.57% | 44.83% | 44.05% | 44.53% | 45.55% | 45.82% | 46.46% | 46.07% | 45.76% | 46.66% | 46.93% | 45.68% | 44.74% | — | — | — | ||||||
Bristol-Myers Squibb Co. | -21.60% | 9.27% | 11.67% | 16.30% | 22.62% | 28.63% | 28.59% | 23.43% | 22.69% | 18.64% | 15.93% | 17.50% | 17.39% | 19.71% | 21.73% | 24.06% | 23.83% | — | — | — | ||||||
Eli Lilly & Co. | 24.69% | 23.55% | 24.48% | 25.64% | 22.29% | 20.00% | 19.48% | 12.50% | 15.15% | 12.34% | 9.11% | 14.88% | 9.38% | 12.43% | 14.23% | 12.92% | 16.30% | — | — | — | ||||||
Gilead Sciences Inc. | — | 11.01% | -4.40% | 19.89% | 19.38% | 19.71% | 38.44% | 37.87% | 37.83% | 42.81% | 46.25% | 51.51% | 55.04% | 58.72% | 58.71% | 58.46% | 58.87% | 61.67% | 63.83% | 66.22% | ||||||
Illumina Inc. | 17.91% | 22.08% | 25.69% | 27.28% | 27.80% | 26.42% | 24.88% | 25.58% | 26.49% | 28.25% | 27.58% | 26.29% | 22.02% | 20.01% | 20.06% | 21.35% | 24.48% | — | — | — | ||||||
Johnson & Johnson | 23.60% | 24.30% | 24.64% | 25.62% | 24.15% | 24.15% | 22.63% | 22.69% | 24.27% | 22.59% | 23.05% | 23.63% | 24.07% | 27.02% | 28.55% | 28.83% | 28.72% | — | — | — | ||||||
Merck & Co. Inc. | 16.47% | 26.87% | 25.40% | 25.49% | 24.77% | 25.56% | 26.73% | 24.38% | 19.62% | 17.84% | 12.28% | 13.57% | 16.28% | 9.92% | 16.85% | 14.45% | 13.51% | — | — | — | ||||||
Pfizer Inc. | 19.47% | 24.77% | 23.75% | 25.38% | 25.46% | 26.30% | 27.50% | 26.86% | 26.10% | 26.18% | 26.00% | 25.86% | 25.92% | 24.69% | 23.57% | 22.94% | 22.73% | — | — | — | ||||||
Regeneron Pharmaceuticals Inc. | 42.09% | 37.43% | 34.64% | 30.45% | 28.10% | 29.55% | 29.58% | 35.41% | 37.77% | 37.00% | 36.89% | 36.54% | 35.41% | 34.22% | 32.29% | 28.76% | 27.38% | — | — | — | ||||||
Vertex Pharmaceuticals Inc. | 46.03% | 44.43% | 38.67% | 34.05% | 28.77% | 21.38% | 25.48% | 23.98% | 20.84% | 22.38% | 3.87% | -0.77% | 4.95% | 1.62% | 16.16% | 14.62% | 0.58% | — | — | — | ||||||
Zoetis Inc. | 33.62% | 33.87% | 33.36% | 32.72% | 31.42% | 31.01% | 29.80% | 30.05% | 31.12% | 33.00% | 33.86% | 33.02% | 32.15% | 29.43% | 28.34% | 28.55% | 28.48% | — | — | — |
Based on: 10-K (filing date: 2021-02-19), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-04), 10-Q (filing date: 2020-05-08), 10-K (filing date: 2020-02-21), 10-Q (filing date: 2019-11-06), 10-Q (filing date: 2019-08-05), 10-Q (filing date: 2019-05-03), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-07), 10-Q (filing date: 2018-08-07), 10-Q (filing date: 2018-05-04), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06).
1 Q4 2020 Calculation
Operating profit margin = 100
× (Operating earningsQ4 2020
+ Operating earningsQ3 2020
+ Operating earningsQ2 2020
+ Operating earningsQ1 2020)
÷ (Net revenuesQ4 2020
+ Net revenuesQ3 2020
+ Net revenuesQ2 2020
+ Net revenuesQ1 2020)
= 100 × (3,753 + 3,255 + 752 + 3,603)
÷ (13,858 + 12,902 + 10,425 + 8,619)
= 24.81%
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | AbbVie Inc.’s operating profit margin ratio deteriorated from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020. |
Net Profit Margin
AbbVie Inc., net profit margin calculation (quarterly data)
Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
Net earnings (loss) attributable to AbbVie Inc. | 36 | 2,308 | (738) | 3,010 | 2,801 | 1,884 | 741 | 2,456 | (1,826) | 2,747 | 1,983 | 2,783 | 52 | 1,631 | 1,915 | 1,711 | 1,391 | 1,598 | 1,610 | 1,354 | ||||||
Net revenues | 13,858 | 12,902 | 10,425 | 8,619 | 8,704 | 8,479 | 8,255 | 7,828 | 8,305 | 8,236 | 8,278 | 7,934 | 7,739 | 6,995 | 6,944 | 6,538 | 6,796 | 6,432 | 6,452 | 5,958 | ||||||
Profitability Ratio | ||||||||||||||||||||||||||
Net profit margin1 | 10.08% | 18.16% | 19.20% | 24.77% | 23.69% | 9.90% | 12.62% | 16.42% | 17.36% | 23.50% | 20.84% | 21.55% | 18.82% | 24.38% | 24.77% | 24.07% | 23.22% | — | — | — | ||||||
Benchmarks | ||||||||||||||||||||||||||
Net Profit Margin, Competitors2 | ||||||||||||||||||||||||||
Abbott Laboratories | 12.99% | 10.50% | 9.89% | 11.15% | 11.56% | 10.50% | 9.36% | 8.53% | 7.74% | 2.91% | 3.13% | 1.67% | 1.74% | 8.37% | 4.96% | 6.74% | 6.71% | — | — | — | ||||||
Amgen Inc. | 29.97% | 30.91% | 31.53% | 33.64% | 35.32% | 36.14% | 35.57% | 35.93% | 37.25% | 9.96% | 10.72% | 10.11% | 9.08% | 37.36% | 37.24% | 36.12% | 35.27% | — | — | — | ||||||
Bristol-Myers Squibb Co. | -21.20% | -0.11% | -1.61% | 3.08% | 13.15% | 23.39% | 26.00% | 22.09% | 21.81% | 6.50% | 1.74% | 4.37% | 4.85% | 20.56% | 22.66% | 24.22% | 22.94% | — | — | — | ||||||
Eli Lilly & Co. | 25.24% | 24.01% | 24.48% | 23.97% | 37.27% | 35.10% | 33.76% | 26.12% | 13.16% | 1.85% | -0.60% | 4.82% | -0.89% | 9.90% | 11.12% | 10.13% | 12.90% | — | — | — | ||||||
Gilead Sciences Inc. | — | 5.56% | -1.18% | 22.17% | 24.35% | 12.24% | 27.14% | 26.93% | 25.16% | 7.27% | 9.69% | 14.26% | 18.03% | 42.90% | 43.55% | 44.11% | 45.07% | 48.40% | 51.16% | 53.48% | ||||||
Illumina Inc. | 20.25% | 19.70% | 20.68% | 26.49% | 28.28% | 28.13% | 27.55% | 25.05% | 24.78% | 21.09% | 20.88% | 19.31% | 26.38% | 30.14% | 30.07% | 30.52% | 19.29% | — | — | — | ||||||
Johnson & Johnson | 17.82% | 21.01% | 18.86% | 20.75% | 18.42% | 17.32% | 20.08% | 17.99% | 18.75% | 1.89% | 1.70% | 1.58% | 1.70% | 21.28% | 22.52% | 22.87% | 23.01% | — | — | — | ||||||
Merck & Co. Inc. | 14.72% | 24.33% | 22.20% | 21.10% | 21.01% | 20.26% | 21.10% | 19.50% | 14.71% | 8.02% | 3.25% | 3.88% | 5.97% | 7.15% | 12.71% | 10.88% | 9.85% | — | — | — | ||||||
Pfizer Inc. | 22.95% | 17.85% | 28.80% | 31.17% | 31.45% | 30.57% | 23.58% | 21.31% | 20.79% | 44.63% | 42.35% | 41.29% | 40.55% | 18.69% | 15.90% | 13.88% | 13.66% | — | — | — | ||||||
Regeneron Pharmaceuticals Inc. | 41.35% | 38.28% | 37.30% | 28.56% | 26.91% | 28.13% | 28.59% | 35.12% | 36.42% | 28.24% | 25.65% | 23.54% | 20.41% | 23.17% | 22.05% | 19.34% | 18.42% | — | — | — | ||||||
Vertex Pharmaceuticals Inc. | 43.70% | 44.91% | 38.51% | 31.35% | 28.27% | 59.23% | 64.13% | 66.01% | 68.80% | 22.87% | 15.84% | 9.36% | 10.59% | 8.53% | 12.19% | 8.78% | -6.58% | — | — | — | ||||||
Zoetis Inc. | 24.54% | 25.42% | 25.50% | 25.41% | 23.96% | 23.76% | 22.74% | 23.47% | 24.52% | 20.35% | 19.95% | 17.97% | 16.28% | 18.29% | 17.50% | 17.25% | 16.80% | — | — | — |
Based on: 10-K (filing date: 2021-02-19), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-04), 10-Q (filing date: 2020-05-08), 10-K (filing date: 2020-02-21), 10-Q (filing date: 2019-11-06), 10-Q (filing date: 2019-08-05), 10-Q (filing date: 2019-05-03), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-07), 10-Q (filing date: 2018-08-07), 10-Q (filing date: 2018-05-04), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06).
1 Q4 2020 Calculation
Net profit margin = 100
× (Net earnings (loss) attributable to AbbVie Inc.Q4 2020
+ Net earnings (loss) attributable to AbbVie Inc.Q3 2020
+ Net earnings (loss) attributable to AbbVie Inc.Q2 2020
+ Net earnings (loss) attributable to AbbVie Inc.Q1 2020)
÷ (Net revenuesQ4 2020
+ Net revenuesQ3 2020
+ Net revenuesQ2 2020
+ Net revenuesQ1 2020)
= 100 × (36 + 2,308 + -738 + 3,010)
÷ (13,858 + 12,902 + 10,425 + 8,619)
= 10.08%
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | AbbVie Inc.’s net profit margin ratio deteriorated from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020. |
Return on Equity (ROE)
AbbVie Inc., ROE calculation (quarterly data)
Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
Net earnings (loss) attributable to AbbVie Inc. | 36 | 2,308 | (738) | 3,010 | 2,801 | 1,884 | 741 | 2,456 | (1,826) | 2,747 | 1,983 | 2,783 | 52 | 1,631 | 1,915 | 1,711 | 1,391 | 1,598 | 1,610 | 1,354 | ||||||
Stockholders’ equity (deficit) | 13,076 | 15,270 | 14,708 | (7,415) | (8,172) | (8,226) | (8,566) | (7,826) | (8,446) | (2,921) | (3,375) | 3,553 | 5,097 | 6,687 | 6,009 | 4,998 | 4,636 | 6,469 | 5,640 | 4,643 | ||||||
Profitability Ratio | ||||||||||||||||||||||||||
ROE1 | 35.30% | 48.34% | 47.30% | — | — | — | — | — | — | — | — | 179.59% | 104.16% | 99.42% | 110.08% | 126.25% | 128.41% | — | — | — | ||||||
Benchmarks | ||||||||||||||||||||||||||
ROE, Competitors2 | ||||||||||||||||||||||||||
Abbott Laboratories | 13.71% | 10.78% | 10.17% | 11.84% | 11.86% | 10.35% | 9.14% | 8.48% | 7.76% | 2.89% | 3.03% | 1.52% | 1.54% | 6.57% | 3.71% | 4.79% | 6.82% | — | — | — | ||||||
Amgen Inc. | 77.20% | 67.09% | 68.48% | 80.92% | 81.07% | 73.83% | 73.73% | 74.55% | 67.15% | 15.35% | 15.86% | 14.21% | 7.84% | 25.37% | 25.77% | 25.76% | 25.85% | — | — | — | ||||||
Bristol-Myers Squibb Co. | -23.84% | -0.09% | -1.15% | 1.91% | 6.66% | 32.04% | 38.65% | 33.80% | 35.07% | 10.50% | 3.05% | 7.18% | 8.58% | 28.61% | 31.20% | 33.55% | 27.55% | — | — | — | ||||||
Eli Lilly & Co. | 109.79% | 115.45% | 137.26% | 179.72% | 319.09% | 234.97% | 282.08% | 252.24% | 32.88% | 3.44% | -1.24% | 7.74% | -1.76% | 14.94% | 17.35% | 15.58% | 19.54% | — | — | — | ||||||
Gilead Sciences Inc. | — | 7.27% | -1.43% | 22.49% | 23.91% | 13.07% | 26.33% | 26.84% | 25.51% | 6.94% | 10.19% | 16.82% | 22.64% | 46.69% | 53.86% | 61.82% | 71.48% | 89.38% | 105.21% | 129.43% | ||||||
Illumina Inc. | 13.98% | 13.57% | 15.19% | 20.32% | 21.72% | 21.92% | 21.65% | 21.36% | 21.98% | 19.53% | 19.90% | 18.85% | 26.41% | 27.38% | 27.54% | 29.01% | 21.06% | — | — | — | ||||||
Johnson & Johnson | 23.25% | 26.35% | 24.11% | 28.01% | 25.42% | 24.31% | 26.87% | 24.90% | 25.60% | 2.39% | 2.18% | 1.97% | 2.16% | 21.39% | 22.71% | 23.46% | 23.49% | — | — | — | ||||||
Merck & Co. Inc. | 27.91% | 39.47% | 37.91% | 38.72% | 37.99% | 34.70% | 33.88% | 30.50% | 23.30% | 10.32% | 4.12% | 4.69% | 6.97% | 7.44% | 12.89% | 10.91% | 9.78% | — | — | — | ||||||
Pfizer Inc. | 15.21% | 13.31% | 22.02% | 24.28% | 25.77% | 24.91% | 21.24% | 19.52% | 17.59% | 33.40% | 32.31% | 29.72% | 29.88% | 16.14% | 14.26% | 12.49% | 12.12% | — | — | — | ||||||
Regeneron Pharmaceuticals Inc. | 31.86% | 31.17% | 32.94% | 18.79% | 19.08% | 20.41% | 21.21% | 25.70% | 27.91% | 22.85% | 22.14% | 21.74% | 19.51% | 21.12% | 20.91% | 19.79% | 20.13% | — | — | — | ||||||
Vertex Pharmaceuticals Inc. | 31.22% | 33.08% | 27.67% | 23.38% | 19.34% | 40.81% | 43.70% | 45.63% | 47.28% | 22.27% | 15.46% | 9.41% | 12.99% | 10.93% | 15.55% | 11.82% | -9.69% | — | — | — | ||||||
Zoetis Inc. | 43.46% | 46.17% | 54.23% | 58.52% | 55.39% | 54.56% | 57.03% | 59.91% | 65.35% | 54.96% | 56.60% | 49.90% | 48.81% | 47.11% | 51.20% | 53.14% | 55.21% | — | — | — |
Based on: 10-K (filing date: 2021-02-19), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-04), 10-Q (filing date: 2020-05-08), 10-K (filing date: 2020-02-21), 10-Q (filing date: 2019-11-06), 10-Q (filing date: 2019-08-05), 10-Q (filing date: 2019-05-03), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-07), 10-Q (filing date: 2018-08-07), 10-Q (filing date: 2018-05-04), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06).
1 Q4 2020 Calculation
ROE = 100
× (Net earnings (loss) attributable to AbbVie Inc.Q4 2020
+ Net earnings (loss) attributable to AbbVie Inc.Q3 2020
+ Net earnings (loss) attributable to AbbVie Inc.Q2 2020
+ Net earnings (loss) attributable to AbbVie Inc.Q1 2020)
÷ Stockholders’ equity (deficit)
= 100 × (36 + 2,308 + -738 + 3,010)
÷ 13,076 = 35.30%
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | AbbVie Inc.’s ROE improved from Q2 2020 to Q3 2020 but then deteriorated significantly from Q3 2020 to Q4 2020. |
Return on Assets (ROA)
AbbVie Inc., ROA calculation (quarterly data)
Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
Net earnings (loss) attributable to AbbVie Inc. | 36 | 2,308 | (738) | 3,010 | 2,801 | 1,884 | 741 | 2,456 | (1,826) | 2,747 | 1,983 | 2,783 | 52 | 1,631 | 1,915 | 1,711 | 1,391 | 1,598 | 1,610 | 1,354 | ||||||
Total assets | 150,565 | 149,621 | 149,530 | 91,199 | 89,115 | 59,441 | 57,142 | 56,769 | 59,352 | 66,164 | 61,641 | 69,342 | 70,786 | 68,840 | 66,994 | 65,664 | 66,099 | 66,626 | 67,211 | 53,720 | ||||||
Profitability Ratio | ||||||||||||||||||||||||||
ROA1 | 3.07% | 4.93% | 4.65% | 9.25% | 8.84% | 5.48% | 7.21% | 9.44% | 9.58% | 11.43% | 10.46% | 9.20% | 7.50% | 9.66% | 9.87% | 9.61% | 9.01% | — | — | — | ||||||
Benchmarks | ||||||||||||||||||||||||||
ROA, Competitors2 | ||||||||||||||||||||||||||
Abbott Laboratories | 6.20% | 4.90% | 4.52% | 5.36% | 5.43% | 4.80% | 4.23% | 3.88% | 3.53% | 1.24% | 1.35% | 0.67% | 0.63% | 2.91% | 1.65% | 2.12% | 2.66% | — | — | — | ||||||
Amgen Inc. | 11.54% | 11.37% | 11.23% | 12.45% | 13.13% | 13.55% | 13.40% | 12.62% | 12.64% | 3.27% | 3.49% | 3.12% | 2.48% | 10.18% | 10.27% | 10.14% | 9.95% | — | — | — | ||||||
Bristol-Myers Squibb Co. | -7.61% | -0.04% | -0.44% | 0.74% | 2.65% | 9.85% | 11.24% | 14.77% | 14.06% | 4.24% | 1.15% | 2.78% | 3.00% | 12.45% | 13.73% | 14.68% | 13.22% | — | — | — | ||||||
Eli Lilly & Co. | 13.28% | 12.68% | 13.39% | 13.46% | 21.17% | 20.97% | 20.28% | 16.46% | 7.36% | 1.01% | -0.34% | 2.53% | -0.45% | 5.17% | 5.98% | 5.81% | 7.05% | — | — | — | ||||||
Gilead Sciences Inc. | — | 2.08% | -0.46% | 8.31% | 8.74% | 4.55% | 9.42% | 9.38% | 8.57% | 2.47% | 3.38% | 5.30% | 6.58% | 17.94% | 20.27% | 21.90% | 23.70% | 26.63% | 32.71% | 36.30% | ||||||
Illumina Inc. | 8.65% | 8.62% | 9.56% | 12.97% | 13.70% | 13.73% | 13.45% | 11.52% | 11.87% | 10.12% | 11.08% | 10.23% | 13.81% | 15.49% | 15.39% | 16.10% | 10.81% | — | — | — | ||||||
Johnson & Johnson | 8.41% | 9.95% | 9.59% | 11.07% | 9.59% | 9.10% | 10.53% | 9.78% | 10.00% | 0.99% | 0.88% | 0.79% | 0.83% | 10.17% | 10.69% | 11.39% | 11.71% | — | — | — | ||||||
Merck & Co. Inc. | 7.72% | 12.83% | 11.56% | 11.95% | 11.66% | 11.18% | 11.15% | 10.20% | 7.53% | 3.93% | 1.58% | 1.84% | 2.72% | 3.11% | 5.48% | 4.50% | 4.11% | — | — | — | ||||||
Pfizer Inc. | 6.23% | 4.85% | 7.96% | 9.49% | 9.72% | 9.51% | 8.10% | 7.38% | 7.00% | 14.19% | 13.67% | 13.21% | 12.40% | 5.70% | 4.94% | 4.32% | 4.20% | — | — | — | ||||||
Regeneron Pharmaceuticals Inc. | 20.47% | 19.62% | 20.68% | 14.46% | 14.29% | 15.38% | 15.71% | 18.88% | 20.83% | 16.64% | 15.99% | 15.23% | 13.67% | 14.69% | 14.24% | 12.32% | 12.84% | — | — | — | ||||||
Vertex Pharmaceuticals Inc. | 23.07% | 23.81% | 20.37% | 16.99% | 14.15% | 28.53% | 31.50% | 32.94% | 33.57% | 14.00% | 9.58% | 5.72% | 7.43% | 6.12% | 7.91% | 6.02% | -3.87% | — | — | — | ||||||
Zoetis Inc. | 12.04% | 12.12% | 12.37% | 13.97% | 12.99% | 12.96% | 12.52% | 12.75% | 13.25% | 11.13% | 12.96% | 11.25% | 10.06% | 10.09% | 11.25% | 11.18% | 10.73% | — | — | — |
Based on: 10-K (filing date: 2021-02-19), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-04), 10-Q (filing date: 2020-05-08), 10-K (filing date: 2020-02-21), 10-Q (filing date: 2019-11-06), 10-Q (filing date: 2019-08-05), 10-Q (filing date: 2019-05-03), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-07), 10-Q (filing date: 2018-08-07), 10-Q (filing date: 2018-05-04), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06).
1 Q4 2020 Calculation
ROA = 100
× (Net earnings (loss) attributable to AbbVie Inc.Q4 2020
+ Net earnings (loss) attributable to AbbVie Inc.Q3 2020
+ Net earnings (loss) attributable to AbbVie Inc.Q2 2020
+ Net earnings (loss) attributable to AbbVie Inc.Q1 2020)
÷ Total assets
= 100 × (36 + 2,308 + -738 + 3,010)
÷ 150,565 = 3.07%
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
ROA | A profitability ratio calculated as net income divided by total assets. | AbbVie Inc.’s ROA improved from Q2 2020 to Q3 2020 but then deteriorated significantly from Q3 2020 to Q4 2020. |